TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00634816

Intervention type: RADIATION
Intervention: DXA Scan
Description: The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
Study: NCT03631043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy Specimen Radiography
Description: Undergo collection of blood and bone marrow
Study: NCT03483961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvanted
Description: Adjuvanted formulation includes Alhydrogel
Study: NCT03631043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy Specimen Radiography
Description: Undergo collection of blood and bone marrow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Therapy
Description: Given personalized vaccine SC
Study: NCT03483961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvanted
Description: Adjuvanted formulation includes Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvanted
Description: Adjuvanted formulation includes Alhydrogel
Study: NCT03631043

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Therapy
Description: Given personalized vaccine SC
Study: NCT03483961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHIKV VLP/adjuvanted
Description: Adjuvanted formulation includes Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is vaccine diluent alone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is vaccine diluent alone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is vaccine diluent alone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is vaccine diluent alone
Study: NCT02484001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL 800 mg
Description: one (1) tablet of 800 mg (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL 1200 mg
Description: one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL 1600 mg
Description: two (2) tablets of 800 mg (QD).
Study: NCT03483961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is vaccine diluent alone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is vaccine diluent alone
Study: NCT02484001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL 400 mg
Description: half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
Study: NCT01698242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Training
Description: PCP-Level: A PCP randomized to the Enhanced Training (ET) group will receive: 1) a full and pocket sized copy of the current AHA Heart Failure (HF) Guidelines; 2) a summary of their patient's data collected at baseline, 6-month, and 30-month in-person study visits; and 3) an invitation to complete the CHART-designed online course in HF management for CME credit.~Patient Level: The ET patient-level intervention uses Community Health Workers (CHWs) to assist the patient in learning self-management behaviors to reduce the risk of hospitalization. The key objectives are to: improve heart failure knowledge; encourage use of HF management tools; and facilitate development of self-management skills. Each participant receives at least: six AHA educational mailings, six monthly home visits, and 18 phone calls by CHWs within the first six months of the intervention. The CHW then conducts monthly telephone visits for the subsequent two years (for a total of 30 months of follow-up).
Study: NCT03798600

Intervention type: DRUG
Intervention: Caspofungin
Description: In accordance with routine clinical practice, Caspofungin will be given at the loading dose of 70 mg followed by 50 mg daily (for people \< 80 kg body weight). No dose reduction will be performed in Child-Pugh score A or B. Duration of therapy will be performed in accordance with ESCMID guidelines and clinical conditions.
Study: NCT01698242

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Education
Description: The Enhanced Education (EE) intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention provides nominal information through the mail. Randomization occurs at the PCP-level; patients are assigned to the EE group only if their PCP already has been randomized to this group.~PCP Level: Upon randomization to the EE group each PCP will receive a full-sized copy of the current American Heart Association (AHA) Heart Failure Guidelines within thirty days after randomization.~Patient Level: Upon their assignment to the EE group, patients will receive: Six AHA Tip-Sheet mailings (one Tip-Sheet to be mailed each of the first six months following group assignment); a telephone call, made by the CHART Research Assistant (RA), completed once during each of the first six months following group assignment and only to confirm that the patient received the Tip-Sheet mailing for that month.
Study: NCT03209622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy delivred in cardiology intensive care unit versus Nicotine replacement therapy delivered after hospital discharge
Description: when patient is admitted in intensive care of cardiology for acute coronary syndrome he is randomized to Arm A or Arm B
Study: NCT04241692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CarnationTM Ambulatory Monitoring Sternal ECG Patch System
Description: A newly developed cardiac rhythm monitoring system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional 24-Hour 7 Lead Holter Monitor Recorder
Description: Traditional recordings made using a standard 24-hour Holter monitor.
Study: NCT03209622

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy delivred in cardiology intensive care unit versus Nicotine replacement therapy delivered after hospital discharge
Description: when patient is admitted in intensive care of cardiology for acute coronary syndrome he is randomized to Arm A or Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Arm A

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the external consultation
Description: without patch
Study: NCT03572816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Settner shoe
Description: custom-made heel-unloading orthosis ('Settner shoe') in aftercare of calcaneus fractures (used according to manufacturer), certified 'CE' product with more than 10 years experience
Study: NCT00519428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: 10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion extra long (XL)
Description: 150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram + bupropion
Description: same dosing schedule as for monotherapy
Study: NCT03119753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Prototyping method of fabrication of complete denture
Description: For Rapid Prototyping Method of fabrication of complete denture : the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method of fabrication of complete denture
Description: For Conventional Method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
Study: NCT01579838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: PNH and or atypical TTP classical protocols
Study: NCT01940900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Study: NCT02081235

Intervention type: PROCEDURE
Intervention: surgery for congenital heart disease
Description: surgery for congenital heart disease
Study: NCT03723343

Intervention type: DRUG
Intervention: GP+IMRT
Description: Gemcitabine 1000 mg/m2 intravenously, d1\&d8 +Cisplatin 80 mg/m2 intravenously, d1 21\~28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases

Intervention type: DRUG
Intervention: TPF+IMRT
Description: Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1\~d5+5-fluorouracil 750mg/m2/d intravenous drip, d1\~d521\~28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
Study: NCT00642837

Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Osteoarthritis, flexible dose depending on patients' pain relief

Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Post surgical neurophatic pain, flexible dose depending on patients' pain relief

Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Post traumatic neuropathic pain, flexible dose depending on patient pain relief

Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Spinal Cord Injury, flexible dose depending on patients' pain relief

Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief

Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Diabetic Neuropathy, flexible dose depending on patients' pain relief

Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Post stroke pain, flexible dose depending on patients' pain relief

Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Low back pain, flexible dose depending on patients' pain relief

Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Post Herpetic Neuralgia, flexible dose depending on patients' pain relief

Intervention type: DRUG
Intervention: Tramadol/acetaminophen
Description: Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
Study: NCT03989947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Description: Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
Study: NCT01163890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work and Health Initiative
Description: Telephone-based multi-modal intervention, consisting of: vocational coaching, cognitive-behavioral therapy strategies and care coordination strategies provided by specially-trained EAP counselors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Medical or Behavioral Intervention
Description: Referral to treatment as usual through personal physician, mental health professional, behavioral health program, and/or Employee Assistance Program
Study: NCT01940900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E10030 sham intravitreal injection
Description: Pressure on the eye with a syringe with no needle
Study: NCT04688086

Intervention type: DIAGNOSTIC_TEST
Intervention: Thermalytix
Description: Thermalytix is an Artificial intelligence based automated breast screening solution that analyzes thermal distribution on the breast to generate a breast health score automatically. Thermal imaging was performed by a trained technician to capture thermal images of the participant in five views. These thermal images were uploaded to Thermalytix software on the cloud where it was automatically analyzed by AI-based Thermalytix computer-aided detection (CADe) engine. This CADe engine analyzes uploaded thermal images and outputs an interpretation report for each participant with quantitative scores corresponding to computed probability of malignancy based on the structural, vascular, areolar, thermal properties of the observed abnormality. Thermalytix also generates annotated images with markings of abnormal regions and an overall Thermalytix score suggesting likelihood of breast malignancy. The locked AI model Thermalytix algorithm version 3, dated December 2018 was used for the analysis.
Study: NCT02189122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bradykinin
Description: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bradykinin
Description: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Study: NCT03151616

Intervention type: OTHER
Intervention: anticholinergic risk scale
Description: Risk summation scale for grading and studying anticholinergic medication exposure

Intervention type: OTHER
Intervention: anticholinergic risk scale
Description: Risk summation scale for grading and studying anticholinergic medication exposure
Study: NCT02189122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Subjects will take Aspirin 81 mg per day for five days.
Study: NCT02166411

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myomectomy using barbed sutures
Description: A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . The myometrial edges will be reapproximated in one or two layers (according to the depth of the uterine wound) by using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: myomectomy using conventional sutures
Description: A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . Myometrial edges will be re-approximated using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ)
Study: NCT01856049

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of umbilical cord blood
Description: Cord blood will be processed in the temperate state it was collected to produce a pure, stem cell product identifiable to patients with Hypoplastic Left Heart Syndrome, and will be stored at a frozen state for their potential, future use in a clinical trial.
Study: NCT04058743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TKA with nickel free components
Description: Patients will be randomized to receive either the standard cobalt chromium components or nickel free components

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TKA with standard cobalt chromium components
Description: Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
Study: NCT02535702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo MRS
Description: 1H MR spectroscopy to assess brain metabolites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo MRS
Description: 1H MR spectroscopy to assess brain metabolites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo MRS
Description: 1H MR spectroscopy to assess brain metabolites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo MRS
Description: 1H MR spectroscopy to assess brain metabolites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo MRS
Description: 1H MR spectroscopy to assess brain metabolites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo MRS
Description: 1H MR spectroscopy to assess brain metabolites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo MRS
Description: 1H MR spectroscopy to assess brain metabolites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo MRS
Description: 1H MR spectroscopy to assess brain metabolites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo MRS
Description: 1H MR spectroscopy to assess brain metabolites.
Study: NCT02189122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 162 mg
Description: Subjects will take aspirin 162 mg per day for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NHP544-C 81 mg
Description: Subjects will take NHP544C 81 mg per day for five days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NHP544C 162 mg
Description: Subjects will take NHP544C 162 mg once a day for five days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will take matching placebo for five days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will take matching placebo for five days.
Study: NCT00649142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open sutured mesh repair
Description: Open sutured mesh repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic mesh glue fixation
Description: Laparoscopic mesh glue fixation
Study: NCT04896502

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Education
Description: Education regarding recognition and removal of in-home asthma triggers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Video (IAV) Telemedicine
Description: Interactive video assessment of asthma triggers in the home.
Study: NCT02292641

Intervention type: PROCEDURE
Group type: OTHER
Intervention: New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery
Description: Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
Study: NCT00581009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chronobiological augmentation
Description: Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline, lithium
Description: Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: one night of sleep deprivation and two FDG PET scans
Description: MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
Study: NCT01013792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound Dressing
Description: Acetate mesh carrier with ointment (water, PEGs)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Dressing
Description: Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)
Study: NCT04524273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inebilizumab
Description: Participants will receive IV inebilizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inebilizumab
Description: Participants will receive IV inebilizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: Participants will receive IV placebo matched to inebilizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: Participants will receive IV placebo matched to inebilizumab
Study: NCT03191149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography with Contrast
Description: Undergo CT with contrast

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO